Total RSV hospital days per 100 children · patients at high risk of severe respiratory syncytial virus infection
1 finding from 1 review
Incidence of admissions to the ICU · patients at high risk of severe respiratory syncytial virus infection
Palivizumab leads to lower admission to ICU compared with placebo (high certainty).
1 finding from 1 review
Mechanical ventilation for RSV infection · patients at high risk of severe respiratory syncytial virus infection
It is very uncertain whether palivizumab changes mechanical ventilation for RSV infection compared with placebo (very low certainty).
1 finding from 1 review
Supplemental oxygen therapy for RSV infection · patients at high risk of severe respiratory syncytial virus infection
1 finding from 1 review
Number of children reporting any SAE · patients at high risk of severe respiratory syncytial virus infection
Palivizumab leads to lower number of children reporting any SAE compared with placebo (high certainty).
1 finding from 1 review
Hospitalisation for RSV infection · patients at high risk of severe respiratory syncytial virus infection
Palivizumab showed no clear difference in hospitalisation for RSV infection compared with motavizumab (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients at high risk of severe respiratory syncytial virus infection
Palivizumab showed no clear difference in all‐cause mortality compared with motavizumab (moderate certainty).
1 finding from 1 review
Intervention not reported
First recurrence · high‐risk melanoma participants
The intervention leads to lower first recurrence (high certainty).
1 finding from 1 review
Intervention not reported
Death · high‐risk melanoma participants
The intervention leads to lower death (high certainty).
1 finding from 1 review
Outcomes · Studies recruited adults and adolescents aged 12 and older with chronic asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations needing hospitalisation · Studies recruited adults and adolescents aged 12 and older with chronic asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations requiring oral corticosteroids ‐ adults · Studies recruited adults and adolescents aged 12 and older with chronic asthma
SiT for maintenance/relief leads to lower patients with exacerbations requiring oral steroids compared with higher‐dose ICS/LABA + SABA (high certainty).
1 finding from 1 review
OR 0.75 [0.65, 0.87]
9096 participants
High
Patients with serious adverse events · Studies recruited adults and adolescents aged 12 and older with chronic asthma
SiT for maintenance/relief showed no clear difference in patients with serious adverse events compared with higher‐dose ICS/LABA + SABA (moderate certainty).
1 finding from 1 review
OR 0.92 [0.74, 1.13]
9130 participants
Moderate
Patients with severe exacerbations (requiring hospitalisation or ER visit) · Studies recruited adults and adolescents aged 12 and older with chronic asthma
SiT for maintenance/relief leads to lower patients with severe exacerbations (requiring hospitalisation or ER… compared with higher‐dose ICS/LABA + SABA (high certainty).
1 finding from 1 review
OR 0.72 [0.57, 0.9]
7768 participants
High
Number of participants experiencing one or more episode requiring treatment with oral steroids · children with asthma
Anti‐leukotrienes & ICS may leads to lower participants with one or more exacerbations requiring oral… compared with higher dose ICS (low certainty).
1 finding from 1 review
Hospital admissions due to exacerbations: number of participants · children with asthma
Anti‐leukotrienes & ICS may leads to higher participants with exacerbations requiring hospital admission compared with higher dose ICS (low certainty).
1 finding from 1 review
Brush biopsy (oral cytology) vs No screening
Outcome not reported · Planned population: general population or high-risk / opportunistic screening groups (no eligible study)
The review found no eligible studies for this question.
1 finding from 1 review
Fluorescence imaging / light-based techniques vs No screening
Outcome not reported · Planned population: general population or high-risk / opportunistic screening groups (no eligible study)
The review found no eligible studies for this question.
1 finding from 1 review
Visual marginal discrepancy (3 years) · Patients receiving single crowns and FDPs; split-mouth
Low-gold (Midas) or silver-palladium (Albacast) alloy FDP showed no clear difference in visual marginal discrepancy (3 years) compared with high-gold content control alloy (JS C) FDP; GRADE not reported.
1 finding from 1 review
Restoration survival · Patients receiving crowns and FDPs; split-mouth, 10-year
Alternative alloy FDP (e.g., Ceramalloy II / base-metal /… led to higher restoration survival (Ceramalloy II versus Olympia) compared with high-gold content control alloy FDP (Olympia); GRADE not reported.
1 finding from 1 review
OR 3.5 [1.4, 8.7]
1 study
GRADE not reported